Axitinib (off Label)
Axitinib vs observation (randomized Phase 2)
Pfizer · Phase 2 · Completed · Enrollment 60
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Axitinib 5 mg twice daily | R/M ACC with progression within 9 months (n = 60 total) | 5 mg | ITT | observation | median progression-free survival: 10.8 months, primary analysis6-month progression-free survival: 73%, 6 monthsprogression-free survival hazard ratio vs observation: 0.25 HR, as reported in ESMO-EURACAN guidelineobjective response rate: 0%, primary analysisdisease control rate: 100%, primary analysis |
| Observation | R/M ACC with progression within 9 months | none | ITT | n/r | median progression-free survival: 2.8 months, primary analysis6-month progression-free survival: 23%, 6 monthsdisease control rate: 51.9%, primary analysismedian overall survival: 27.2 months, axitinib median not reached; P 0.226 |